| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
29,132 |
25,951 |
$1.56M |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
38,875 |
34,343 |
$1.47M |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
8,469 |
8,405 |
$751K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
8,545 |
8,488 |
$709K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
6,366 |
6,319 |
$614K |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
6,677 |
6,435 |
$542K |
| 90460 |
Immunization administration through 18 years of age via any route, first or only component |
40,485 |
16,936 |
$473K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
11,796 |
11,324 |
$172K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
7,966 |
3,856 |
$116K |
| 87428 |
|
1,332 |
1,303 |
$108K |
| 99381 |
|
1,068 |
1,051 |
$90K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
9,892 |
7,165 |
$83K |
| 99215 |
Prolong outpt/office vis |
826 |
787 |
$71K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
1,493 |
1,463 |
$68K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
659 |
652 |
$61K |
| 99383 |
|
534 |
530 |
$51K |
| 90461 |
|
10,367 |
8,844 |
$45K |
| 80061 |
Lipid panel |
2,929 |
2,881 |
$32K |
| 99429 |
|
786 |
784 |
$29K |
| 99382 |
|
296 |
293 |
$28K |
| 97169 |
|
1,037 |
1,029 |
$28K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
1,055 |
1,020 |
$27K |
| 83655 |
|
2,427 |
2,406 |
$27K |
| 92551 |
|
15,428 |
15,303 |
$27K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
163 |
160 |
$24K |
| 87807 |
|
1,890 |
1,801 |
$21K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
323 |
319 |
$20K |
| 99384 |
|
193 |
193 |
$20K |
| 99000 |
|
1,693 |
1,623 |
$18K |
| G8510 |
Screening for depression is documented as negative, a follow-up plan is not required |
1,443 |
1,387 |
$17K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
1,183 |
1,154 |
$14K |
| 99460 |
|
138 |
134 |
$11K |
| 82947 |
|
2,867 |
2,818 |
$10K |
| 96160 |
|
5,941 |
5,833 |
$10K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
545 |
529 |
$7K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
203 |
201 |
$7K |
| 99462 |
|
148 |
101 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
508 |
432 |
$6K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
59 |
58 |
$5K |
| 90620 |
|
1,407 |
1,404 |
$4K |
| 85018 |
|
3,569 |
3,543 |
$3K |
| 81003 |
|
1,725 |
1,613 |
$3K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
35 |
34 |
$3K |
| 96161 |
|
983 |
977 |
$3K |
| 87631 |
|
14 |
14 |
$2K |
| 81025 |
|
233 |
224 |
$2K |
| 96380 |
|
84 |
84 |
$2K |
| 90651 |
|
2,396 |
2,387 |
$1K |
| 97802 |
|
17,948 |
17,684 |
$497.29 |
| 86308 |
|
105 |
101 |
$484.81 |
| 90686 |
|
4,299 |
4,272 |
$393.85 |
| 90734 |
|
1,134 |
1,128 |
$360.57 |
| 92587 |
|
18 |
17 |
$245.66 |
| A7003 |
Administration set, with small volume nonfiltered pneumatic nebulizer, disposable |
294 |
285 |
$230.89 |
| 90472 |
Immunization administration, each additional vaccine (list separately) |
19 |
12 |
$218.54 |
| S8301 |
Infection control supplies, not otherwise specified |
17 |
17 |
$176.00 |
| 90619 |
|
1,287 |
1,278 |
$159.58 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
93 |
77 |
$146.77 |
| CP002 |
|
14 |
12 |
$137.20 |
| 90715 |
|
1,360 |
1,350 |
$78.96 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
529 |
517 |
$22.14 |
| 90671 |
|
441 |
441 |
$0.27 |
| 90677 |
|
1,162 |
1,147 |
$0.03 |
| 90670 |
|
4,057 |
4,052 |
$0.01 |
| 90707 |
|
2,827 |
2,812 |
$0.00 |
| 99173 |
|
11,264 |
11,188 |
$0.00 |
| 90633 |
|
2,997 |
2,983 |
$0.00 |
| 90700 |
|
1,316 |
1,305 |
$0.00 |
| 90710 |
|
12 |
12 |
$0.00 |
| 90672 |
|
61 |
59 |
$0.00 |
| 90380 |
|
24 |
24 |
$0.00 |
| 96127 |
|
397 |
300 |
$0.00 |
| 90716 |
|
2,815 |
2,799 |
$0.00 |
| 90647 |
|
2,742 |
2,735 |
$0.00 |
| 90660 |
|
40 |
40 |
$0.00 |
| 90697 |
|
2,145 |
2,135 |
$0.00 |
| 90696 |
|
1,357 |
1,351 |
$0.00 |
| 90680 |
|
3,689 |
3,677 |
$0.00 |
| S9451 |
Exercise classes, non-physician provider, per session |
16,503 |
16,386 |
$0.00 |
| 90656 |
|
581 |
579 |
$0.00 |
| 90723 |
|
2,085 |
2,081 |
$0.00 |
| 90381 |
|
83 |
82 |
$0.00 |